Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on
Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen
The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC), recently approved by the FDA, has been shown in four Phase III trials to be effective as initial therapy
The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits.
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were
Release from correctional settings is a high-stakes time for persons with HIV, as it is for those with other health issues. People with substance use disorders often relapse, and those with HIV often
Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen.
HPV oral and oropharyngeal cancers are more difficult to detect than tobacco-related cancers because the symptoms are not always obvious to an individual, and health professionals may lack the education and background to diagnose HPV-related lesions. Although there are many adjunctive oral cancer screening devices and tests, none of them can currently detect early-stage HPV-positive oral and oropharyngeal cancers. My rule of thumb: Any lesion that persists for 2 weeks should be referred to an oral medicine specialist or oral surgeon to evaluate and biopsy, if indicated.
While enrolled in graduate school at the Rutgers University School of Nursing, I continued to work as registered nurse on a labor and delivery unit at an increasingly busy community hospital in central New Jersey. Though my unit boasts delivery rates exceeding 2,000 births per year, most of our patients are middle-class, low-risk women in their 30's giving birth to planned pregnancies carried to term. Though not a new nurse, at the time I was new to the labor unit, and happened to be on my final days of orientation when I received report on a primigravida in her early 20's in active labor.